E04.1 - Large-scale proteomics and human genetics

Value of the Information & Strength of the Argument

The talk provides valuable insights into the application of Mendelian randomization to proteomics, highlighting both its utility and potential pitfalls. The argumentation is solid, grounded in specific examples and data from published studies. The speaker effectively demonstrates the power of MR to assess causality and the importance of careful interpretation, especially when observational and genetic evidence diverge. He also emphasizes the need for rigorous validation of protein measurements, which is a critical but often overlooked aspect.

Scientific Rigor, Source Quality, Title Accuracy

The speaker is a recognized expert, and the content is consistent with current scientific literature. He cites specific studies and collaborations, though he does not provide detailed references during the talk. The title accurately reflects the content, which focuses on the intersection of proteomics and genetics. The talk is scientifically rigorous, but as a conference presentation, it lacks the formal citation structure of a peer-reviewed article.

The title accurately reflects the content, which focuses on the integration of large-scale proteomics with human genetics.

8/10

Talk by a leading researcher in the field, presenting established methods (Mendelian randomization) and recent large-scale studies. The content is technically sound and reflects current scientific consensus, though it is a conference presentation rather than a peer-reviewed publication.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction: Speaker Adam Butterworth, University of Cambridge, topic: large-scale proteomics and human genetics.
• 05:00Early work on C-reactive protein (CRP) and cardiovascular disease; observational associations and risk prediction.
• 10:00Introduction to Mendelian randomization (MR) and its application to CRP; finding no causal effect on coronary heart disease.
• 15:00Study on interleukin-6 receptor (IL6R) and its causal effect on coronary heart disease; pleiotropic effects on other diseases.
• 20:00Transition to large-scale proteomics: SomaLogic panel measuring 3,500 proteins; discovery of thousands of pQTLs.
• 25:00Case study of MMP12: observational vs. causal direction; replication across platforms and studies.
• 30:00Scaling up: GWAS of 3,000 proteins in 35,000 UK Biobank participants; public availability of data.
• 35:00Proteome-wide MR during COVID-19; testing 1,500 proteins and 15,000 transcripts.
• 40:00Challenges: ensuring correct protein measurement; example of ALPL/LTF misidentification.
• 45:00Challenges: protein complexes and different proteoforms; example with proteinase 3 and alpha-1-antitrypsin.

• UK Biobank — Mentioned as a source of large-scale genetic and proteomic data.
• SomaLogic — Platform used for measuring thousands of proteins.
• Olink — Alternative platform for protein measurement.

• Sun et al. (2018) Genomic atlas of the human plasma proteome — One of the first large-scale pQTL studies, mentioned in the talk.
• Ferkingstad et al. (2021) Large-scale integration of the plasma proteome with genetics and disease — Icelandic study on pQTLs, mentioned in the talk.